Australian mRNA capability recognised by US genetic medicines program

22 October 2026 Australian mRNA capability recognised by US genetic medicines program What if fully personalised genetic medicines could be manufactured close to the patients who need them within a week? An Australian research facility has been selected for a US program aiming to make personalised genetic medicines faster and more accessible. The BASE mRNA […]
The infrastructure enabling cell therapy access for Australian patients

17 September 2026 The infrastructure enabling cell therapy access for Australian patients A powerful cellular immunotherapy developed by Professor Rajiv Khanna AO and his team at QIMR Berghofer and manufactured at Q-Gen Cell Therapeutics is saving lives.  The therapy targets severe viral infections caused by common viruses such as Epstein-Barr Virus that can become life […]
New antimalarial drug candidate reaches early clinical milestone

11 September 2026 New antimalarial drug candidate reaches early clinical milestone A new antimalarial drug candidate showing encouraging early clinical results is demonstrating how Australia’s national research infrastructure is helping move promising discoveries closer to new treatments. Findings from two early clinical studies show the drug candidate is well tolerated in humans and achieves blood […]
Celebrating Multiple TIA-supported MRFF NCRI Successes

Updated 25 August 2026 Therapeutic Innovation Australia (TIA) is pleased to congratulate several outstanding Australian research teams on their successful MRFF 2024 National Critical Research Infrastructure (NCRI) grant applications. TIA, enabled by the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS), is proud to support these initiatives, helping to bridge the gap between research discoveries […]
TIA-supported facility helps drive global effort to develop new therapies for mitochondrial disease

7 August 2026 The TIA-supported National Biologics Facility will play a key role in the only non-European node of a major international collaboration developing new therapies for mitochondrial disease. New genetic medicines have the potential to transform the lives of people living with devastating mitochondrial diseases, rare genetic disorders that currently have few treatment options. […]
From Discovery to Clinical Trials: How NCRIS Is Accelerating a Breakthrough in Ovarian Cancer Detection

21 July 2026 This breakthrough work is bringing lifesaving early‑detection tools closer to reality  Professor John Hooper and his team at Mater Research Institute and The University of Queensland are bringing new hope to women with ovarian cancer through the development of innovative imaging agents designed to detect the disease earlier, when treatment is […]
Small Changes, Big Impact: How Research Infrastructure is Rethinking Sustainability in the Laboratory

7 July 2026 What if one of the most effective ways to reduce the environmental footprint of a research laboratory was as simple as changing a freezer setting? Drug Discovery Research Infrastructure facilities are exploring practical ways to improve the environmental sustainability and operational efficiency of laboratory research while maintaining the quality and integrity of […]
NCRIS: Celebrating 20 Years of Research Support and Innovation

2 July 2026 Celebrating 20 years of NCRIS: Reflecting on two decades of nationally coordinated research infrastructure Therapeutic Innovation Australia was proud to join colleagues from across Australia’s research infrastructure community to celebrate the 20th anniversary of the National Collaborative Research Infrastructure Strategy (NCRIS). The milestone was marked through a series of events in Canberra […]
Pipeline Accelerator 2025-26 Round 2 Outcomes

19 June 2026 Therapeutic Innovation Australia (TIA), in partnership with Phenomics Australia, Bioplatforms Australia and ANSTO’s National Deuteration Facility, is thrilled to announce the successful recipients of the Pipeline Accelerator 2025-26 (Round 2). Enabled by the National Collaborative Research Infrastructure Strategy (NCRIS), these four NCRIS providers are working in partnership to help address the medical products challenge […]
Accelerating therapeutic translation through coordinated national infrastructure

7 April 2026 Accelerating therapeutic translation through coordinated national infrastructure Australia produces world-class biomedical research, but many discoveries face barriers progressing beyond early development due to limited access to infrastructure, expertise, and early-stage funding. Therapeutic Innovation Australia’s (TIA) Pipeline Accelerator Program, enabled by NCRIS, addresses this gap by providing coordinated access to national research infrastructure […]
Supporting the journey of bioengineered heart tissue

2 April 2026 From feasibility to clinical translation: supporting the journey of bioengineered heart tissue Therapeutic Innovation Australia’s (TIA) voucher program has supported early-stage work that helped enable the new spin-out, Ibnova Therapeutics, which is advancing a stem cell–based treatment for heart failure towards human clinical trials within the next three to five years. The company builds […]
New research reveals promising target to slow aggressive cancers

31 March 2026 Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) have uncovered a potential new way to slow aggressive cancers by targeting a specialised process called minor splicing. The discovery draws on screening capabilities at the National Drug Discovery Centre, a facility supported by Therapeutic innovation Australia (TIA) through the National Collaborative […]
The story behind the headlines: a glimpse into personalised RNA therapeutics

19 March 2026 The story behind the headlines: a glimpse into personalised RNA therapeutics This recent story from has captured global attention. At its centre is Rosie, a dog diagnosed with an incurable cancer, and her owner, tech entrepreneur Paul Conyngham, who worked with researchers across the University of New South Wales (UNSW) and The […]
A nasal spray to protect against COVID-19 and future respiratory viruses

12 March 2026 A nasal spray to protect against COVID-19 and future respiratory viruses The UNSW RNA Institute, a facility supported by Therapeutic Innovation Australia through Australia’s National Collaborative Research Infrastructure Strategy (NCRIS) , and in partnership with the Office of the NSW Chief Scientist & Engineer, is helping researchers develop new antiviral therapies that could […]
AI/ML Across TIA-supported facilities

10 March 2026 Artificial Intelligence and Machine Learning Across TIA-supported facilities: Building Capability for Translation Across the Therapeutic Innovation Australia (TIA) network, artificial intelligence (AI) and machine learning (ML) are increasingly embedded into existing workflows to support more efficient research translation. While these approaches are often described as emerging technologies, many TIA-supported facilities have been […]
Griffith University Secures $3M NHMRC Funding to Launch the Centre of Research Excellence in Vaccine ADD

28 January 2026 Griffith University Secures NHMRC Funding to Launch the Centre of Research Excellence in Vaccine Adjuvant Discovery and Development. Therapeutic Innovation Australia (TIA) congratulates Professor Katherine Andrews and Associate Professor Danielle Stanisic from Griffith University on the successful funding of their NHMRC Centre of Research Excellence in Vaccine Adjuvant Discovery and Development (Vaccine-ADD). Funded at $3 million over five years, Vaccine-ADD […]